Google
English
French
German
Italian
Japanese
Portuguese
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection
Oxford, UK, April 26th, 2023 — Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been granted FDA Breakthrough Device Status for its AI-enhanced platform for detecting cardiac amyloidosis.
The platform, EchoGo Amyloidosis, uses artificial intelligence to analyze echocardiograms and detect the presence of cardiac amyloidosis, a condition caused by deposits of abnormal proteins in the heart tissue, using only a single commonly acquired ultrasound view of the heart.
myBinderRelated Content
-
Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis: Progress and HopeCardiac amyloidosis is an infiltrative d...
-
Van Selby, MDDr. Van Selby is a cardiologist who spec...
-
Stephen Heitner, MDStephen Heitner is a Senior Medical Dire...
-
Barry Trachtenberg: Advanced Heart Failure Therapies in Cardiac Amyloidosis – ASG Webinar 1.25.24 – 4/9https://www.youtube.com/watch?v=A9g6r1PQ...
-
Cardiac Amyloidosis – the Great Imitatorhttps://www.youtube.com/watch?v=7DQotydY...
-
Implanted Cardiac Defibrillator and Pacemaker Lead Function in Patient With Cardiac AmyloidosisIntroduction: Cardiac amyloidosis (CA...
-
Increasing Rate of Hospital Admissions in Patients with Amyloidosis (From the National Inpatient Sample)Cardiac amyloidosis is an increasingly...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
